MARKET NEWS

Boehringer Ingelheim & OSE Immunotherapeutics Announce First Patient Dosed in Phase 1 Expansion Trial of SIRPα Antagonist Monoclonal Antibody BI 765063 in Combination With Anti-PD-1 Antibody Ezabenlimab, in Patients With Advanced Endometrium or Colorectal Tumors
Castle Creek Biosciences Expands its Innovative Gene Therapy Platform for Rare Genetic Connective Tissue Disorders Through Research Collaboration With Mayo Clinic
Adaptive Biotechnologies Launches Enhanced clonoSEQ Assay Reports for Patients With Chronic Lymphocytic Leukemia, Now Featuring IGHV Mutation Status
Starton Therapeutics Announces Successful Results in STAR-LLD Toxicology Study: No Myelosuppression & Excellent Tolerability
Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, & Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia
Catalent Opens New Full-Service Clinical Supply Facility in Shiga, Japan

  FEATURED EDITORIAL

  COMPANY PROFILE

ILC Dover is a world-leader in the innovative design and production of engineered flexible protective solutions, for pharmaceutical and biopharmaceutical, flood protection, personal protection, bulk packaging, and aerospace industries. Our customers will attest to our relentless dedication to high value products, advanced technology, and responsive service, as our visionary solutions have improved efficiency while safeguarding people, product, and infrastructure in hazardous conditions since 1947. Our focus in the pharmaceutical industry is to facilitate safe and reliable performance in the lab while ensuring maximum productivity with single-use flexible powder solutions for high containment. Click here for more.

  EXCLUSIVE ONLINE CONTENT

MilliporeSigma Launches Excipient Technology Platform for Viscosity Reduction of Protein-Based Therapeutics

MilliporeSigma Launches Excipient Technology Platform for Viscosity Reduction of Protein-Based Therapeutics

MilliporeSigma has recently launched a new Viscosity Reduction Excipient Platform to reduce the viscosity and help overcome manufacturing and formulation challenges associated with….

MannKind Announces First Patient Enrolled in INHALE-1 Study of Afrezza in Pediatric Population

MannKind Announces First Patient Enrolled in INHALE-1 Study of Afrezza in Pediatric Population

MannKind Corporation recently announced the enrollment of the first pediatric patient in the INHALE-1 study. The multi-center study will evaluate the efficacy and safety of….

InMed Pharmaceuticals Announces Commencement of Phase 2 Clinical Trial Investigating Cannabinol (CBN), a Rare Cannabinoid, in the Treatment of Epidermolysis Bullosa

InMed Pharmaceuticals Announces Commencement of Phase 2 Clinical Trial Investigating Cannabinol (CBN), a Rare Cannabinoid, in the Treatment of Epidermolysis Bullosa

InMed Pharmaceuticals Inc. recently announced it has commenced its Phase 2 clinical trial of INM-755 (cannabinol) cream in the treatment of Epidermolysis Bullosa (“EB”). This marks the first time….

Avacta Group Announces Achievement of Preclinical Development Milestone in LG Chem Life Sciences Partnership

Avacta Group Announces Achievement of Preclinical Development Milestone in LG Chem Life Sciences Partnership

Avacta Group plc recently announced a preclinical development milestone has been achieved in the multi-target therapeutics development partnership with LG Chem Life Sciences, the life sciences division of the South Korean LG Group, triggering an….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

October 20 – Capsules
October 27 – Analytical Testing